Related references
Note: Only part of the references are listed.2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B. Besse et al.
ANNALS OF ONCOLOGY (2014)
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2013)
European cancer mortality predictions for the year 2013
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2013)
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
Athanasios Karampeazis et al.
CANCER (2013)
Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients
Yihua Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
Mauro Zukin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
Fabrice Barlesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Study finds different efficacy for afatinib in non-small-cell lung cancer cases with EGF receptor mutations
[Anonymous]
LUNG CANCER MANAGEMENT (2013)
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
Chee Khoon Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Prospects for population screening and diagnosis of lung cancer
John K. Field et al.
LANCET (2013)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2013)
Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer
Tokujiro Yano et al.
LUNG CANCER (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adrenalectomy for solid tumor metastases: Results of a multicenter European study
Pablo Moreno et al.
SURGERY (2013)
Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
European cancer mortality predictions for the year 2012
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2012)
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
Natasha Rekhtman et al.
CLINICAL CANCER RESEARCH (2012)
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial
Cesare Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
Paul W. Sperduto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid Subgroup Analysis from a Randomized Phase 3 Study
Giorgio Vittorio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Radical Treatment of Non-Small-Cell Lung Cancer Patients with Synchronous Oligometastases Long-Term Results of a Prospective Phase II Trial (Nct01282450)
Dirk De Ruysscher et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
Siow Ming Lee et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Pemetrexed plus Platinum as the First-Line Treatment Option for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Ming Li et al.
PLOS ONE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer A Systematic Review and Meta-analysis
Xinji Zhang et al.
CHEST (2011)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Elisabeth Quoix et al.
LANCET (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Andre Bacellar Costa Lima et al.
PLOS ONE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer
Jennifer S. Temel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
Andrew N. Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Massimo Di Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
Rogerio Lilenbaum et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Giorgio Scagliotti et al.
ONCOLOGIST (2009)
Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: A systematic review and pooled analysis
Tawee Tanvetyanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer
Joon Oh Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I study with exploratory pharmacodynamic endpoints of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients (pts) with advanced solid malignancies
H. A. Wakelee et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Lung cancer incidence in never smokers
Heather A. Wakelee et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity
Chee-Keong Toh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based?: A meta-analysis of phase III randomized trials
JL Pujol et al.
LUNG CANCER (2006)
Annual report to the Nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
BK Edwards et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Use of silicone stents in the management of tracheobronchial stenosis due to tuberculosis
Y Ryu et al.
CHEST (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion
CM Dresler et al.
CHEST (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
C Gridelli et al.
ANNALS OF ONCOLOGY (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1
G Robinet et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
